Search research articles
Contact Us
Filters
Showing results (1-10 of 50) with videos related to
Page
of 5
Sort By:
Contemporary Clinical Trials Communications
|
May 10, 2018
Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab
Paul Delmar, Cornelia Irl, Lu Tian
Bioinformatics (Oxford, England)
|
September 18, 2004
VarMixt: efficient variance modelling for the differential analysis of replicated gene expression data
Paul Delmar, Stéphane Robin, Jean Jacques Daudin
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Jinglin Zhong, David Li, Paul Delmar, et al.
Current Medical Research and Opinion
|
October 9, 2018
Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients
Jessica Davies, Michael Martinec, Mathieu Coudert, et al.
Pharmaceutical Statistics
|
April 17, 2024
Rejoinder to the letter: "Standard and reference-based conditional mean imputation: Regulators and trial statisticians be aware!"
Marcel Wolbers, Alessandro Noci, Paul Delmar, et al.
Pharmaceutical Statistics
|
December 29, 2017
Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects
David Dejardin, Paul Delmar, Charles Warne, et al.
Pharmaceutical Statistics
|
May 19, 2022
Standard and reference-based conditional mean imputation
Marcel Wolbers, Alessandro Noci, Paul Delmar, et al.
Contemporary Clinical Trials
|
May 8, 2013
An industry statistician's perspective on PHC drug development
Jane Fridlyand, Ru-Fang Yeh, Howard Mackey, et al.
Journal of Comparative Effectiveness Research
|
June 27, 2018
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Jessica Davies, Michael Martinec, Paul Delmar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 21, 2015
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer
Denis Soulières, Fred R Hirsch, Frances A Shepherd, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 50) with videos related to
Sort By:
Page
of 5
Contemporary Clinical Trials Communications
|
May 10, 2018
Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab
Paul Delmar, Cornelia Irl, Lu Tian
Bioinformatics (Oxford, England)
|
September 18, 2004
VarMixt: efficient variance modelling for the differential analysis of replicated gene expression data
Paul Delmar, Stéphane Robin, Jean Jacques Daudin
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Jinglin Zhong, David Li, Paul Delmar, et al.
Current Medical Research and Opinion
|
October 9, 2018
Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients
Jessica Davies, Michael Martinec, Mathieu Coudert, et al.
Pharmaceutical Statistics
|
April 17, 2024
Rejoinder to the letter: "Standard and reference-based conditional mean imputation: Regulators and trial statisticians be aware!"
Marcel Wolbers, Alessandro Noci, Paul Delmar, et al.
Pharmaceutical Statistics
|
December 29, 2017
Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects
David Dejardin, Paul Delmar, Charles Warne, et al.
Pharmaceutical Statistics
|
May 19, 2022
Standard and reference-based conditional mean imputation
Marcel Wolbers, Alessandro Noci, Paul Delmar, et al.
Contemporary Clinical Trials
|
May 8, 2013
An industry statistician's perspective on PHC drug development
Jane Fridlyand, Ru-Fang Yeh, Howard Mackey, et al.
Journal of Comparative Effectiveness Research
|
June 27, 2018
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Jessica Davies, Michael Martinec, Paul Delmar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 21, 2015
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer
Denis Soulières, Fred R Hirsch, Frances A Shepherd, et al.
Page
of 5